Serena Marchetti

1.8k citations
48 papers · 1.4k · h-index 19

Impact in

  • Oncology top 5%
    • Drug Transport and Resistance Mechanisms
    • PARP inhibition in cancer therapy
    • Cancer Treatment and Pharmacology
  • Pharmacology top 5%
    • Pharmacogenetics and Drug Metabolism

Papers in

  • Oncology 41
    • Cancer Treatment and Pharmacology 12
    • Drug Transport and Resistance Mechanisms 11
    • Colorectal Cancer Treatments and Studies 10
    • PARP inhibition in cancer therapy 7
  • Molecular Biology 21
    • Cancer therapeutics and mechanisms 10
Co-authors
Jan H.M. Schellens (36 shared papers)Jos H. Beijnen (38 shared papers)Roberto Mazzanti (10 shared papers)Dick Pluim (12 shared papers)Olaf van Tellingen (6 shared papers)Gabe S. Sonke (6 shared papers)Robin M.J.M. van Geel (6 shared papers)Hilde Rosing (16 shared papers)
Journals
Journal of Clinical Oncology (6 papers)Investigational New Drugs (5 papers)Cancer Chemotherapy and Pharmacology (4 papers)Clinical Cancer Research (2 papers)European Journal of Cancer (2 papers)
Partner nations
NetherlandsItalyUnited States

In The Last Decade

Serena Marchetti

47 papers receiving 1.3k citations

Peers

Serena Marchetti
Comparison fields: 5 of 103
  • Oncology 836
  • Pharmacology 155
  • Reproductive Medicine 85
  • Molecular Biology 577
  • Pediatrics, Perinatology and Child Health 151
Replace Li Yu with:
Li Yu China
Jason A. Sprowl United States
Ammar C. Al‐Rikabi Saudi Arabia
Anne T. Reutens Australia
Suoping Zhai United States
Linda L. Garland United States
Kouichi Kurose Japan
Hyun Jo Youn South Korea
Lu-Bin Lan United States
Takenori Takahata Japan
Serena Marchetti relative to Li Yu China Li Yu's profile →
Citations per field
00.5×2×3.1×
Li Yu · 1×
Citations per year

Countries citing papers authored by Serena Marchetti

Since Specialization
Citations

This map shows the geographic impact of Serena Marchetti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Serena Marchetti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Serena Marchetti more than expected).

Fields of papers citing papers by Serena Marchetti

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Serena Marchetti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Serena Marchetti. The network helps show where Serena Marchetti may publish in the future.

Co-authors

The 25 scholars most cited alongside Serena Marchetti, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Serena Marchetti Line = papers co-authored together Serena Marchetti links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 48 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months
Journal of Clinical Oncology ·Suzanne Leijen, Robin M.J.M. van Geel, Gabe S. Sonke, Daphne de Jong, Efraim H. Rosenberg, Serena Marchetti, Dick Pluim, Erik van Werkhoven, Shelonitda Rose, Mark A. Lee, Tomoko Freshwater, Jos H. Beijnen, Jan H.M. Schellens
2016239
2
Concise Review: Clinical Relevance of Drug–Drug and Herb–Drug Interactions Mediated by the ABC Transporter ABCB1 (MDR1, P-glycoprotein)
The Oncologist ·Serena Marchetti, Roberto Mazzanti, Jos H. Beijnen, Jan H.M. Schellens
2007215
3
Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition inin vitroandin vivopharmacokinetic studies employing Bcrp1−/−/Mdr1a/1b−/− (triple-knockout) and wild-type mice
Molecular Cancer Therapeutics ·Serena Marchetti, Nienke A. de Vries, Tessa Buckle, Maria J. Bolijn, Maria A.J. van Eijndhoven, Jos H. Beijnen, Roberto Mazzanti, Olaf van Tellingen, Jan H.M. Schellens
2008161
4
Neurofunctional dopaminergic impairment in elderly after lifetime exposure to manganese
NeuroToxicology ·Roberto G. Lucchini, Stefano Guazzetti, Silvia Zoni, Chiara Benedetti, Chiara Fedrighi, Marco Peli, Filippo Donna, Elza Bontempi, Laura Borgese, Serena Micheletti, Roberta Ferri, Serena Marchetti, Donald R. Smith
201476
5
Hepatocyte Growth Factor and Inducible Nitric Oxide Synthase Are Involved in Multidrug Resistance–Induced Angiogenesis in Hepatocellular Carcinoma Cell Lines
Cancer Research ·Nadia Lasagna, Ornella Fantappiè, Michela Solazzo, Lucia Morbidelli, Serena Marchetti, Greta Cipriani, Marina Ziche, Roberto Mazzanti
200649
6
The Effect of St John’s Wort on the Pharmacokinetics of Docetaxel
Clinical Pharmacokinetics ·Andrew K.L. Goey, Irma Meijerman, Hilde Rosing, Serena Marchetti, Marja Mergui‐Roelvink, Marianne Keessen, Jacobus A. Burgers, Jos H. Beijnen, Jan H.M. Schellens
201348
7
The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use
European Journal of Cancer ·Silvy da Rocha Dias, Tomas Salmonson, Barbara van Zwieten‐Boot, Bertil Jönsson, Serena Marchetti, Jan H.M. Schellens, Rosa Giuliani, Francesco Pignatti
201344
8
Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer
British Journal of Cancer ·Ruud van der Noll, Serena Marchetti, Neeltje Steeghs, Jos H. Beijnen, Marja Mergui‐Roelvink, Emmy Harms, Harriet Rehorst, Gabe S. Sonke, Jan H.M. Schellens
201541
9
Abcc4 Together with Abcb1 and Abcg2 Form a Robust Cooperative Drug Efflux System That Restricts the Brain Entry of Camptothecin Analogues
Clinical Cancer Research ·Fan Lin, Serena Marchetti, Dick Pluim, Dilek Iusuf, Roberto Mazzanti, Jan H.M. Schellens, Jos H. Beijnen, Olaf van Tellingen
201338
10
Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer
British Journal of Cancer ·Robin M.J.M. van Geel, Emilie M.J. van Brummelen, Ferry A.L.M. Eskens, Sanne C.F.A. Huijberts, Filip De Vos, Martijn P. Lolkema, Lot A. Devriese, Frans L. Opdam, Serena Marchetti, Neeltje Steeghs, Kim Monkhorst, Bas Thijssen, Hilde Rosing, Alwin D. R. Huitema, Jos H. Beijnen, René Bernards, Jan H.M. Schellens
202027
11
The Use of Dried Blood Spots for Pharmacokinetic Monitoring of Vemurafenib Treatment in Melanoma Patients
The Journal of Clinical Pharmacology ·Cynthia M. Nijenhuis, Alwin D. R. Huitema, Serena Marchetti, Christian U. Blank, John B.A.G. Haanen, Johannes V. van Thienen, Hilde Rosing, Jan H.M. Schellens, Jos H. Beijnen
201627
12
Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer
Cancer Chemotherapy and Pharmacology ·Sanne C.F.A. Huijberts, Robin M.J.M. van Geel, Emilie M.J. van Brummelen, Frans L. Opdam, Serena Marchetti, Neeltje Steeghs, Saskia Pulleman, Bas Thijssen, Hilde Rosing, Kim Monkhorst, Alwin D. R. Huitema, Jos H. Beijnen, René Bernards, Jan H.M. Schellens
202026
13
Phase I study of olaparib in combination with carboplatin and/or paclitaxel in patients with advanced solid tumors.
Journal of Clinical Oncology ·Ruud van der Noll, Joo Ern Ang, Agnes Jager, Serena Marchetti, Marja Mergui‐Roelvink, Johann S. de Bono, Martijn P. Lolkema, André T. Brunetto, Hendrik‐Tobias Arkenau, Maja J. De Jonge, D. van der Biessen, Ilian Tchakov, Karin Bowen, Jan H.M. Schellens
201326
14
Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer
The Oncologist ·Emilie M.J. van Brummelen, Sanne C.F.A. Huijberts, Carla M.L. van Herpen, Ingrid M.E. Desar, Frans L. Opdam, Robin M.J.M. van Geel, Serena Marchetti, Neeltje Steeghs, Kim Monkhorst, Bas Thijssen, Hilde Rosing, Alwin D. R. Huitema, Jos H. Beijnen, René Bernards, Jan H.M. Schellens
202024
15
In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2
Molecular Cancer Therapeutics ·Serena Marchetti, Roos L. Oostendorp, Dick Pluim, Monique van Eijndhoven, Olaf van Tellingen, Alfred H. Schinkel, Richard Versace, Jos H. Beijnen, Roberto Mazzanti, Jan H.M. Schellens
200724
16
A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir
European Journal of Cancer ·Vincent A. de Weger, Frederik E. Stuurman, Jeroen J. M. A. Hendrikx, Johannes J. Moes, Emilia Sawicki, Alwin D. R. Huitema, Bastiaan Nuijen, Bas Thijssen, Hilde Rosing, Marianne Keessen, Marja Mergui‐Roelvink, Jos H. Beijnen, Jan H.M. Schellens, Serena Marchetti
201722
17
The effect of Echinacea purpurea on the pharmacokinetics of docetaxel
British Journal of Clinical Pharmacology ·Andrew K.L. Goey, Irma Meijerman, Hilde Rosing, Jacobus A. Burgers, Marja Mergui‐Roelvink, Marianne Keessen, Serena Marchetti, Jos H. Beijnen, Jan H.M. Schellens
201321
18
Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA
Investigational New Drugs ·Serena Marchetti, Dick Pluim, Monique van Eijndhoven, Olaf van Tellingen, Roberto Mazzanti, Jos H. Beijnen, Jan H.M. Schellens
201320
19
Transtympanic Sodium Thiosulfate for Prevention of Cisplatin-Induced Ototoxicity: A Randomized Clinical Trial
Otology & Neurotology ·Charlotte W. Duinkerken, Vincent A. de Weger, Wouter A. Dreschler, Lisette van der Molen, Dick Pluim, Hilde Rosing, Bastiaan Nuijen, Michael Hauptmann, Jos H. Beijnen, Alfons J. M. Balm, Jan Paul de Boer, Jacobus A. Burgers, Serena Marchetti, Jan H.M. Schellens, Charlotte L. Zuur
202118
20
Disposition and metabolism of 14C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors
Cancer Chemotherapy and Pharmacology ·Anne-Charlotte Dubbelman, Alana L. Upthagrove, Jos H. Beijnen, Serena Marchetti, Eugene Tan, Kimberly Krone, Suraj Anand, Jan H.M. Schellens
201216

About Serena Marchetti

Serena Marchetti is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Pediatrics, Perinatology and Child Health and Cancer Research, having authored 48 papers that have together received 1.4k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (12 papers), Drug Transport and Resistance Mechanisms (11 papers), Colorectal Cancer Treatments and Studies (10 papers), Cancer therapeutics and mechanisms (10 papers), Pharmacological Effects and Toxicity Studies (7 papers), PARP inhibition in cancer therapy (7 papers), Lung Cancer Treatments and Mutations (6 papers) and Pharmacogenetics and Drug Metabolism (5 papers). The work is most often cited by research in Oncology (836 citations), Pharmacology (155 citations), Reproductive Medicine (85 citations), Molecular Biology (577 citations) and Pediatrics, Perinatology and Child Health (151 citations). Serena Marchetti has collaborated with scholars based in Netherlands, Italy and United States. Frequent co-authors include Jan H.M. Schellens, Jos H. Beijnen, Roberto Mazzanti, Dick Pluim, Olaf van Tellingen, Gabe S. Sonke, Robin M.J.M. van Geel, Hilde Rosing, Erik van Werkhoven and Suzanne Leijen. Their work appears in journals such as Journal of Clinical Oncology, Investigational New Drugs, Cancer Chemotherapy and Pharmacology, Clinical Cancer Research and European Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Li YuBreakdown of academic impact, for papers by Jason A. SprowlBreakdown of academic impact, for papers by Ammar C. Al‐RikabiBreakdown of academic impact, for papers by Anne T. ReutensBreakdown of academic impact, for papers by Suoping ZhaiBreakdown of academic impact, for papers by Linda L. GarlandBreakdown of academic impact, for papers by Kouichi KuroseBreakdown of academic impact, for papers by Hyun Jo YounBreakdown of academic impact, for papers by Lu-Bin LanBreakdown of academic impact, for papers by Takenori Takahata